Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Business News › Caris Life Sciences Inks CDx Collaboration With Debiopharm

Caris Life Sciences Inks CDx Collaboration With Debiopharm

May 30, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Caris Life Sciences today announced a strategic collaboration with Debiopharm International to develop a companion diagnostic for an oncology drug being developed by the Swiss biopharmaceuticals firm.

The firms will use Caris' Molecular Intelligence (MI) Transcriptome assay for mRNA analysis to detect rare fibroblast growth factor receptor (FGFR) fusions and identify eligible patients for Debiopharm's FUZE phase II clinical trial of Debio 1347, a selective FGFR inhibitor.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

What's Popular?

In Molecular Diagnostics

  1. Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

  2. Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

    Premium

  3. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  4. Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

  5. HPV, p16 May Offer Different Prognostic Clues in Oropharyngeal Cancer, ESMO Data Reveals

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.